CADL
Candel Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$474.06M
P/E Ratio
—
EPS
$-0.72
Beta
-0.81
52W High
$7.66
52W Low
$4.34
50-Day MA
$5.34
200-Day MA
$5.55
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
43.48
PEG Ratio
—
About Candel Therapeutics Inc
Candel Therapeutics Inc. is an innovative biotechnology firm specializing in oncolytic virus technology to create localized therapies that effectively target cancerous cells while safeguarding healthy tissue. Focused on boosting anti-tumor immunity, Candel's robust pipeline offers solutions for a range of challenging malignancies, reflecting its commitment to overcoming treatment obstacles in oncology. Backed by a comprehensive intellectual property portfolio and strategic collaborations with prominent research institutions, Candel is well-positioned to lead transformative developments in cancer care, ultimately enhancing patient outcomes and advancing the field of oncology.
Fundamentals
| Revenue (TTM) | 31,000 |
| Gross Profit (TTM) | $-23.07M |
| EBITDA | $-47.33M |
| Operating Margin | 0.00% |
| Return on Equity | -64.60% |
| Return on Assets | -26.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.95 |
| Price-to-Book | 9.14 |
| Price-to-Sales (TTM) | 436.42 |
| EV/Revenue | 821.98 |
| EV/EBITDA | -0.01 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $73.27M |
| Float | $63.31M |
| % Insiders | 15.79% |
| % Institutions | 33.10% |
Historical Volatility
HV 10-Day
139.43%
HV 20-Day
98.98%
HV 30-Day
89.61%
HV 60-Day
81.46%
HV Rank
94.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($18.88 target)
7
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/2/2026